Part ofhealthcare →

FEDERALhearing transcript

High Impact

House Subcommittee Hearing on Drug Pricing Transparency

Original title: IMPROVING DRUG PRICING TRANSPARENCY AND LOWERING PRICES FOR AMERICAN CONSUMERS

January 1, 2021

healthcare drug pricing pharmaceuticals transparency legislation

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

The Frame

What this does

This hearing reviewed legislative proposals that could change how drug manufacturers and pharmacy benefit managers disclose pricing and discount information, directly impacting the regulatory environment for pharmaceutical costs.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

Pharmaceutical Manufacturers

The proposed legislation would require new disclosures regarding drug pricing and manufacturing.

Pharmacy Benefit Managers

The proposed legislation includes requirements for the public disclosure of drug discounts.

American Consumers

The legislative goals aim to influence the final costs of prescription drugs.

What changed

Last recorded activity January 1, 2021.

What's next

Next step not available in the current record.

Summary

The House Subcommittee on Health held a hearing on May 21, 2019, to discuss legislative proposals aimed at increasing transparency in drug pricing and reducing costs for consumers. The session included testimony from pharmaceutical industry representatives, medical organizations, and policy experts regarding several proposed bills.

Key Facts

The hearing was held on May 21, 2019, by the Subcommittee on Health of the Committee on Energy and Commerce.
The hearing focused on four specific legislative proposals: H.R. 2064, H.R. 2069, H.R. 2087, and H.R. 2115.
H.R. 2064 proposes amendments to title XI of the Social Security Act concerning manufacturers of drugs, devices, and biologicals.
H.R. 2069 is titled the 'Stopping the Pharmaceutical Industry from Keeping drugs Expensive Act'.
H.R. 2087 is titled the 'Drug Price Transparency Act'.
H.R. 2115 is titled the 'Public Disclosure of Drug Discounts Act'.
Witnesses included representatives from the pharmaceutical industry, the Coalition of State Rheumatology Organizations, Families USA, Arnold Ventures, and the American Action Forum.

Frequently Asked Questions

What was the purpose of this hearing?

The hearing was held to discuss legislative proposals aimed at improving transparency in drug pricing and lowering costs for American consumers.

Which bills were discussed?

The subcommittee reviewed H.R. 2064, H.R. 2069, H.R. 2087, and H.R. 2115.

Why It Matters

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Discoveries

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift90% confidence

Legislative Focus on Transparency

The hearing demonstrates a coordinated effort in 2019 to introduce multiple bills simultaneously targeting drug pricing transparency.

H.R. 2064 H.R. 2069 H.R. 2087 H.R. 2115

Connected Entities

organizationPharmaceutical Research and Manufacturers of America“Industry trade group represented by witness Lisa Meengs Joldersma”Map →

personMichael C. Burgess“Ranking Member of the Subcommittee on Health”Map →

personAnna G. Eshoo“Chairwoman of the Subcommittee on Health”Map →

Sources

Open source document

www.govinfo.gov

Analysis Score

0–100

Significance85
How much this matters to a regular citizen
Controversy60
Intensity of disagreement among stakeholders
Entertainment10
Compellingness for a non-policy-wonk reader
Buzz20
Current news / social attention level

Publisher tools